2026-05-30T02:51:39Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/206342026-03-13T07:58:58Zcom_10630_2254col_10630_37959

Amyloid-b seeding and propagation processes in a hAb-KI model of Alzheimer's disease Trujillo-Estrada, Laura Isabel Do Huynh, Kelly Minh Thu Nguyen, Marie Cheung, Alwin Pham Tran, Janine Núñez-Díaz, Cristina Forner, Stefania Martini, Alessandra C. Da Cunha, Celia Shahnawaz, Mohammad Soto, Claudio Moreno-González, Inés Gutiérrez-Pérez, Antonia LaFerla, Frank Baglietto-Vargas, David Alzheimer, enfermedad de Recent evidence indicates that Aβ can misfold and aggregate into seeds that structurally corrupt native proteins, mimicking a prion-like process. Several studies using FAD animal models have demonstrated that intracerebral infusion of brain extracts from APP-transgenic mice or AD patients induce Aβ deposition and cerebral amyloid angiopathy. To carry out most of these Aβ-seeding studies, APP-transgenic animal have been used. Nevertheless, it remains to be elucidated whether Aβ deposition can be induced by Aβ-seeds in a sporadic AD model that does not overexpress APP and produces wild type human Aβ. We used an innovative model to better understand the amyloidogenic events that occur in sporadic AD. This hAβ-KI model, expresses wild-type human Aβ under the control of the endogenous mouse APP gene. Aβ-seeds from AD patients (stage C) from the AD Research Center (UCI) were administered into 7-8-month-old hAβ-KI and as positive controls 3xTg-AD mice were employed. We demonstrated that amyloid seeds can stimulate Aβ aggregations in 3xTg-AD and hAβ-KI models. We found that Aβ aggregates occur earlier in the 3xTg-AD vs hAβ-KI and that a longer term of treatment is necessary to accelerate diffusible Aβ pathology in the hAβ-KI mice. Thereferoe, this hAβ-KI model represents an important step towards the development of next-generation animal models that will provide better predictive outcomes for human patients. Grants support: UCI MIND Pilot project (DBV), Ministry of Science PID2019-108911RA-100 (DBV), U54 AG054349 (FML), Institute of Health Carlos III PI18/01557 (AG) co-financed by FEDER funds (European Union), NIH/NIA Grant P50 AG16573 (UCI-ADRC). 2020-12-17T17:35:51Z 2020-12-17T17:35:51Z 2020-12 2020-12-17 conference output https://hdl.handle.net/10630/20634 eng Neurodegenerative diseases: Biology and therapeutics Congreso virtual 02/12/202-04/12/2020 open access